Shares of Eli Lilly soared Thursday morning after the pharmaceutical giant announced a clinical trial of its once-daily ...

Shares of Novo Nordisk, the Danish pharmaceutical company behind weight-loss drugs Ozempic and Wegovy, plummeted this week.

In a new First Opinion essay, Borio and Krause, both once top FDA officials, say the commissioner made a “rookie misstep” in ...

The tortoise (Eli Lilly) has caught the hare (Novo Nordisk), according to a report from BMO Capital Markets, which cites the ...

The agency and Novo Nordisk, which makes Ozempic, said Monday that they had learned about "several hundred units" of the drug ...

Rybelsus reduced the risk of cardiovascular-related death, heart attack, and stroke by 14% compared to a placebo over an ...

Novo Nordisk , the producer of Ozempic, Wegovy and other medications, will invest 6.4 billion reais ($1.09 billion) in Brazil ...

At the recent ATTD 2025 meeting, participants discussed recent progress and remaining challenges in developing a fully closed ...

In its fourth quarter 2024 investor letter, Artisan Global Opportunities Fund emphasized stocks such as Novo Nordisk A/S (NYSE:NVO). Novo Nordisk A/S (NYSE:NVO) engages in the research and ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

Novo Nordisk A/S NVO on Saturday presented the ... in adults with type 2 diabetes and PAD, at the American College of Cardiology’s (ACC) Annual Scientific Session and Expo.

Novo Nordisk has experienced a 50% drop due to potential tariffs and recent clinical trial results but remains strong in diabetes treatment, insulin, and GLP-1 products. I outline the bull case ...